Evidence map›Paper›PMID 37368093›Full record

Trial reportInternational journal of clinical oncology2023

Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.

Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita and 7 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Mitsuhiko OtaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hiroshi SaekiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan. h-saeki@gunma-u.ac.jp.ORCID http://orcid.org/0000-0001-7243-6960
Hideo UeharaDepartment of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yoshiko MatsudaDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
Satoshi TsutsumiDepartment of Surgery, Oita Prefectural Hospital, Oita, Japan.
Tetsuya KusumotoDepartment of Gastroenterological Surgery and Clinical Research Institute Cancer Research Division, National Kyushu Medical Center, Fukuoka, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Yasunari UbukataDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Shohei YamaguchiDepartment of Surgery, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
Hiroyuki OritaDepartment of Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan.
Naoki IzawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Saburo KakizoeDepartment of Surgery, Ilikai Medical INC Kakizoe Hospital, Hirado, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
Masaki MoriTokai University School of Medicine, Isehara, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu University · JPGunma University · JPKobe University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPKobe City Medical Center General Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPOita Prefectural Hospital · JPSaiseikai Nakatsu Hospital · JPSan-ikukai Hospital · JPSt. Marianna University School of Medicine · JPTokai University · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrectomy with D2 dissection and adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer (LAGC) in Asia. However, administering chemotherapy with sufficient intensity after gastrectomy is challenging. Several trials demonstrated the efficacy of neoadjuvant chemotherapy (NAC). However, limited studies explored the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) evaluated the safety and efficacy of NAC-SOX in patients with LAGC aged ≥ 70 years.

methodsPatients received three cycles of SOX

resultsThe median age of 26 enrolled patients was 74.5 years. The median DI in NAC-SOX

conclusionsNAC-SOX

Indexed as

Neoadjuvant TherapyStomach NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantGastrectomyHumansNeoplasm Recurrence, LocalOxaliplatinOxaliplatinClinical TrialGastrectomyGastric CancerNeoadjuvant ChemotherapyOlder PersonPhase 2

Identifiers

PMID37368093
PMCPMC10468941
OpenAlexW4382181199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.